Project Grant R44AI192080
Award Date 8/1/25
Completion Date 1/31/26
Dollars Obligated $314K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Blacksburg, VA, USA
Similar Awards
- This Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), is supporting the development of a novel, targeted small molecule inhibitor of the nucleoside salvage pathway to treat systemic lupus erythematosus (SLE). The total funding amount is $994,978, with the award period running from Aug 7, 2025 to Jul 31, 2028. The awardee, Trethera Corp, is a clinical-stage...
- This $600,000 project grant from the National Institute of Allergy and Infectious Diseases will support General Nanotherapeutics LLC's development of nanoimmunotherapy for chronic immune-mediated diseases. The company will leverage nanoparticles to target and expand immunoregulatory cells ex vivo and assess their ability to suppress effector immune responses and induce remission in vivo, including in a lupus model. This proof-of-concept work aligns with the Allergy and Infectious Diseases...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $149,008 Cooperative Agreement under the Trans-NIH Research Support program (CFDA 93.310) to Cartesian Therapeutics Inc. to develop and evaluate a novel cell therapy for the treatment of systemic lupus erythematosus (SLE). The funding will support a Phase 2A clinical trial and the design of a subsequent randomized, placebo-controlled Phase 2B trial to test "Descartes-08", an RNA-engineered chimeric antigen...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to determine the therapeutic potential of CpG-B oligonucleotides (ODNs) for the management of systemic lupus erythematosus (SLE). The $132,930 award, active from January 2025 to July 2028, will support in vitro and in vivo studies using MRL/lpr and humanized mouse models to investigate how CpG-B ODNs, which mimic bacterial...
- This federal Project Grant award of $2,989,958 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Thomas Jefferson University's Sidney Kimmel Medical College. The grant supports research to delineate the mechanisms by which pyrimidine synthesis promotes systemic autoimmunity in systemic lupus erythematosus (SLE). The research aims to improve understanding of the role of pyrimidine...
- This $558,045 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research at Beth Israel Deaconess Medical Center, Inc. (Bidmc) to investigate how the enzyme protein phosphatase 2A (PP2A) controls the function of T cells and contributes to the development of systemic lupus erythematosus (SLE). The research aims to determine how PP2A regulates metabolic enzymes involved in...
- This $256,808 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to better define the molecular mechanisms that cause and perpetuate systemic lupus erythematosus (SLE). The University of Washington is conducting this research, which focuses on analyzing altered mRNA splicing in SLE neutrophils and exploring the consequences of these splicing changes, including...
- This federal Project Grant award for $3,364,935.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) through the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to functionally and mechanistically characterize genetic factors that contribute to the development of systemic lupus erythematosus (SLE). The research aims to elucidate the role of autophagy, a cellular process, in the pathogenesis of SLE, particularly in immune cells and...
- This Project Grant award of $423,500 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to develop novel antibodies that target autoreactive B cells as a potential therapeutic approach for treating systemic lupus erythematosus (SLE) patients, particularly among the African American population. The key objectives are to determine the autoantigen specificity and clinical relevance of...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $555,774.00 to the University of Alabama at Birmingham (UAB) over a 5-year period starting November 19, 2024. The award supports research to investigate the role of the aryl hydrocarbon receptor (AhR) pathway in regulating the development of T-bet+ B cells, which are implicated in the pathogenesis of systemic lupus...